[68Ga]Ga-FAPI-04 PET/CT 在 [18F]FDG 阴性或可疑的原发灶不明患者中的附加作用
这项单中心前瞻性临床研究于2020年3月至2022年3月在西南医科大学附属医院开展,纳入44例因原发灶不明接受[18F]FDG PET/CT且结果为阴性或可疑的患者,重复进行[68Ga]Ga-FAPI PET/CT。结果显示,[68Ga]Ga-FAPI PET/CT在13例[18F]FDG可疑患者中明确了诊断,并在17例[18F]FDG阴性患者中发现了原发灶;44例中14例两种示踪剂均未检出原发灶。作者认为[68Ga]Ga-FAPI PET/CT在识别原发灶不明病变方面显示出很大潜力,并有可能提高[18F]FDG阴性或可疑患者的原发灶检出率。
要点
- 44例[18F]FDG阴性或可疑的原发灶不明患者中,13例经[68Ga]Ga-FAPI PET/CT明确诊断。
- [68Ga]Ga-FAPI PET/CT在17例[18F]FDG阴性患者中额外发现了原发灶。
- 94个淋巴结转移灶的SUVmax均值FAPI 9.2±5.1 vs FDG 7.9±4.8(p=0.03),TBR均值FAPI 9.1±5.2 vs FDG 4.9±3.1(p<0.01)。
核心结论
- [68Ga]Ga-FAPI PET/CT在识别原发灶不明病变方面显示出很大潜力,并有可能提高[18F]FDG阴性或可疑患者的原发灶检出率。
研究设计与样本
- 单中心前瞻性临床研究,于2020年3月至2022年3月在西南医科大学附属医院开展。
- 共纳入44例因原发灶不明接受[18F]FDG PET/CT且结果为阴性或可疑的患者,重复进行[68Ga]Ga-FAPI PET/CT。
- 对FAPI阳性病变采用组织病理学检查、手术或临床随访(至少3个月)进行验证。
主要发现
- 44例患者中位年龄57±12(标准差)岁,男性22例(50%)。
- 44例中13例[18F]FDG PET/CT结果为可疑,经[68Ga]Ga-FAPI PET/CT明确诊断。
- [68Ga]Ga-FAPI PET/CT在另外17例[18F]FDG阴性患者中发现了原发灶。
- 44例中14例两种示踪剂均未检出原发灶。
- 分析了94个淋巴结转移灶,[68Ga]Ga-FAPI PET/CT与[18F]FDG PET/CT的SUVmax均值分别为9.2±5.1与7.9±4.8(p=0.03),TBR均值分别为9.1±5.2与4.9±3.1(p<0.01)。
关键数值与推荐
- 44例中13例[18F]FDG可疑患者经[68Ga]Ga-FAPI PET/CT明确诊断。
- 44例中17例[18F]FDG阴性患者经[68Ga]Ga-FAPI PET/CT发现原发灶。
- 94个淋巴结转移灶SUVmax均值:[68Ga]Ga-FAPI PET/CT 9.2±5.1 vs [18F]FDG PET/CT 7.9±4.8(p=0.03)。
- 94个淋巴结转移灶TBR均值:[68Ga]Ga-FAPI PET/CT 9.1±5.2 vs [18F]FDG PET/CT 4.9±3.1(p<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [18F]FDG PET/CT to detect unknown primary lesions is essential for clinical management but still has limitations. [68Ga]Ga-FAPI is a tumor-stromal imaging agent that provides a promising alternative to [18F]FDG for the assessment of malignancies. We aimed to investigate whether [68Ga]Ga-FAPI PET/CT has an additional role in identifying unknown primary lesions with negative or equivocal [18F] FDG PET/CT results. METHODS: This single-center prospective clinical study was conducted between March 2020 and March 2022 at Southwest Medical University Hospital. Patients underwent [18F]FDG PET/CT for the identification of unknown primary lesions. They underwent repeat [68Ga]Ga-FAPI PET/CT when [18F]FDG PET/CT results were negative or equivocal. Histopathological examination, surgery, or clinical follow-up (at least 3 months) for FAPI-positive lesions. The diagnostic efficacy of [68Ga]Ga-FAPI in identifying unknown primary lesions was evaluated. RESULTS: A total of 44 participants (median age, 57 ± 12 [SD]; 22 [50%] men) were evaluated. Thirteen of the 44 patients had equivocal [18F]FDG PET/CT findings, while the diagnosis was clear on [68Ga]Ga-FAPI PET/CT. [68Ga]Ga-FAPI PET/CT also revealed primary lesions in additional 17 patients with negative [18F]FDG PET/CT findings. In fourteen of 44 patients, no primary lesion was detected by either tracer. On this basis, we analyzed 94 lymph node metastatic lesions. The mean SUVmax of lymph node metastases on [68Ga] Ga-FAPI PET/CT and [18F]FDG PET/CT were 9.2 ± 5.1, 7.9 ± 4.8 (p = 0.03) and the mean TBR were 9.1 ± 5.2, 4.9 ± 3.1 (p < 0.01), respectively. CONCLUSION: [68Ga]Ga-FAPI PET/CT showed great potential for identifying unknown primary lesions and has the potential to improve the detection rate of unknown primary lesions with negative or equivocal for [18F]FDG findings. TRIAL REGISTRATION: ClinicalTrial.gov. Identifier: ChiCTR2100044131.
引用
- Shu Q, Deng M, Hu M, et al. The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG. Eur J Nucl Med Mol Imaging. 2023. PMID: 36609606. doi:10.1007/s00259-022-06095-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。